Last edition
News about "Feng Ren"
Insilico Medicine to Present ISM6331 Phase 1 Data at ESMO 2026
Insilico Medicine will present phase 1 data for Artificial Intelligence (AI)-designed pan-TEAD inhibitor ISM6331 at ESMO 2026 in mesothelioma and advanced solid tumors.
Feng Ren | 28/07/2026 | By News Bureau
Insilico Medicine Advances AI-Discovered IPF Drug Rentosertib into Phase III Clinical Trial
Rentosertib, formerly known as ISM001-055/INS018_055, is a potentially first-in-class oral small-molecule inhibitor targeting TNIK (TRAF2 and NCK-interacting kinase) for the treatment of IPF, a progressive and irreversible lung disease with limited treatment options.
Feng Ren | 08/07/2026 | By Abha | 246
Insilico Begins Phase 1 Trial of AI-Designed NLRP3 Inhibitor ISM8969
Insilico Medicine has completed first-in-human dosing of its AI-designed NLRP3 inhibitor ISM8969 in a phase 1 clinical trial. The oral, brain-penetrant therapy is being developed with Hygtia Therapeutics for chronic neuroinflammation and CNS disorders, including Parkinson’s disease, marking a key milestone in AI-driven drug development.
Feng Ren | 18/06/2026 | By News Bureau
Insilico Medicine and Ribo Partner on AI-Powered RNA Therapeutics Development
Insilico Medicine and Ribo partner to accelerate RNA interference and oligonucleotide drug development using Artificial Intelligence (AI)I-powered discovery platforms and automated laboratory technologies.
Feng Ren | 13/05/2026 | By News Bureau | 162
TaiGen Biotechnology doses first participant in Phase I trial of ISM4808, an AI-designed oral therapy from Insilico Medicine for chronic kidney disease-related anemia.
Feng Ren | 09/03/2026 | By News Bureau | 243
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy